Royal Medical Center is a physician-led nationwide telehealth practice centered on hormone therapy that also offers a compounded tirzepatide weight-loss program (no semaglutide).
- TirzepatideFrom $450/mo
Assume we may earn a commission, at no cost to you. Partners we work with carry a small, fixed edge in where they are listed; the scores themselves are not adjusted.
- Semaglutide
- Not disclosed
- Tirzepatide
- From $450/mo (2.5 mg dose, compounded)
- Coverage
- Not disclosed
- Brand-name
- Compounded only
The scorecard
Royal Medical Center scored on our six published factors. See the methodology.
What we like
- Physician founder Dr. Dagoberto Rodriguez, MD — Emory residency, former Coral Springs Medical Center chairman, U Miami faculty
- Tirzepatide pricing fully itemized by dose tier ($450 / $650 / $800 / $1,100) — more transparent than 'starting at' floors
- All-inclusive pricing bundles medication, supplies, injections, lab monitoring, and physician follow-ups
- Broad catalog (HRT, TRT, peptides, ED, hair, vitamins) reflects an established multi-program clinic
- Florida physician with 30+ years of practice — a strong physician-led care signal
The caveats
- Operating legal entity not disclosed — only the 'Royal Medical Center' brand surfaced
- Pharmacy partner not named — buyers can't verify licensure or 503A/503B status
- No LegitScript badge displayed
- States served not enumerated — site says 'nationwide' with no state list
- Headline 'starting at $116/mo' conflicts with the actual $450/mo tirzepatide floor
The verdict
Best for: Shoppers who want credentialed MD founder with itemized dose-strength pricing.
Ranked #427 of 548 providers we have reviewed — for comparison, read the CoreAge Rx review, ranked #1. In the ranking it sits between Noom Med at #426, 55/100 above and RxPepsDirect at #428, 55/100 below, with the Shapely write-up the next one down.
If that review leaves you undecided, the 7 programs we rank against Royal Medical Center are graded on the same six factors and listed in score order. For the wider picture, our tirzepatide board ranks the field on the same six factors. We have also compared it head to head: CoreAge Rx vs Royal Medical Center goes to CoreAge Rx, 94/100 to 55/100.
Compare Royal Medical Center
Compare with other providers
The closest reviews to Royal Medical Center by Verdict Score — the realistic shortlist if you are weighing this one up.
- #430Teleios Health— Teleios Health is a physician-led, cash-pay GLP-1 weight-loss platform marketing compounded semaglutide from $99/mo and compounded tirzepatide from $139/mo, delivered direct to your door through a fully…55/100
- #431TideMedix— TideMedix is an online prescription-wellness service offering GLP-1 weight care — semaglutide and tirzepatide — through an online assessment and licensed-provider review when clinically appropriate.55/100
- #432Nouri— Nouri is a DTC telehealth platform offering compounded semaglutide and tirzepatide bundled with nutrition and movement planning plus clinician messaging — lifestyle support included rather than upsold.55/100
- #433Peter MD— A physician-prescribed telehealth brand with tiered semaglutide pricing and a discounted tirzepatide first month — restrictions vary by treatment, excluding several states, and its own marketing page understates them.52/100
- #434WellMedr— Names its fulfillment pharmacy and its clinical group in writing, and puts the compounding warning on the pricing page instead of the footer — then publishes no rate anyone can actually be charged, and answers its own FAQ question “Are these medications FDA approved?” with “Yes.”52/100
- #435FORM (by GBY)— The broadest multi-vertical catalog in this ranking — compounded and brand GLP-1s, longevity peptides and hair loss — but its advertised Wegovy "$95/mo" is a membership fee only, not the drug cost.54/100
Pricing, states and verification reflect Royal Medical Center's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on Royal Medical Center's site. Not medical advice; see our disclosure.